Diabetes Screening in Patients on Long-Term Glucocorticoid Therapy
Glucocorticoids are widely prescribed in the treatment of many inflammatory, autoimmune or allergic diseases, but also in transplant patients or patients with malignant hematological diseases (leukaemia, lymphoma, myeloma, etc.). They have many side effects, including effects on carbohydrate metabolism. Corticosteroids
| Condition(s) | Glucocorticosteroid, Diabetes |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Glucocorticoids are widely prescribed in the treatment of many inflammatory, autoimmune or allergic diseases, but also in transplant patients or patients with malignant hematological diseases (leukaemia, lymphoma, myeloma, etc.). They have many side effects, including effects on carbohydrate metabolism. Corticosteroids are diabetogenic because they disrupt pancreatic insulin secretion and decrease the insulin sensitivity of target tissues (liver, muscle, adipose tissue). The use of glucocorticoids may lead to the development of corticosteroid-induced diabetes in non-diabetic patients. Corticosteroid-induced diabetes is frequently found in clinical practice. Incidence figures for corticosteroid-induced diabetes vary widely. Case-control studies show odds ratios of corticosteroid-induced dia |
| Who can participate | Inclusion Criteria: * Person who has orally provided voluntary informed consent. * Patient with an indication for prolonged corticosteroid therapy (more than three months) * Non-diabetic patient Exclusion Criteria: * Person not affiliated to or not benefiting from national health insurance system * Person subject to legal protection (guardianship, curatorship) * Pregnant or breastfeeding woman * Adult unable to provide consent * Minor * Evidence of fasting venous blood glucose greater than 1.26 g/L, or Glycated haemoglobin greater than 6.5% at the time of initial blood sampling before glucocorticoid treatment. * Patient who had received corticosteroid therapy within 3 months prior to the study * Patient with hemoglobin less than 10 g/dL |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Centre Hospitalier Universitaire Dijon |
| Locations | Dijon, France |
| Start date | 2020-02-06 |
| NCT ID | NCT04258293 |
| Official listing | https://clinicaltrials.gov/study/NCT04258293 |